Reviva Pharmaceuticals to Participate in the Upcoming January Virtual Investor Conferences

Rhea-AI Summary

Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) has announced that Laxminarayan Bhat, Ph.D., its Founder and CEO, will participate in upcoming conferences in January. These include the 11th Annual LifeSci Partners Corporate Access Event from January 5-7 and the H.C. Wainwright BioConnect Virtual Conference from January 10-13. Investors are invited to join virtual one-on-one meetings with the CEO. Reviva focuses on developing therapies for CNS, cardiovascular, metabolic, and inflammatory diseases, with drug candidates RP5063 and RP1208 in its pipeline.

CUPERTINO, Calif., Dec. 20, 2021 (GLOBE NEWSWIRE) -- Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) (“Reviva” or the “Company”), a clinical-stage pharmaceutical company developing therapies that seek to address unmet medical needs in the areas of central nervous system (CNS), cardiovascular, metabolic, and inflammatory diseases, today announced that Laxminarayan Bhat, Ph.D., Founder, President, and CEO of Reviva will participate in the following conferences in January and invites investors to participate in virtual one-on-one meetings. Please see additional details below:

11^th Annual LifeSci Partners Corporate Access Event
Wednesday, January 5^th - Friday, January 7^th Registration Link
To submit one-on-one meeting requests Click Here

H.C. Wainwright BioConnect Virtual Conference
Monday, January 10^th - Wednesday, January 13^th Registration Link
A webcast will be available for 90 days on the Events & Presentations section of the Reviva website on January 10^th at 7am ET or by using the following link:
https://journey.ct.events/view/60fae5e9-6fa6-4ddb-bec0-abaff8a708f6

If you are interested in arranging a one-on-one meeting, please contact your conference representative.

About Reviva
Reviva is a clinical-stage biopharmaceutical company that discovers, develops and seeks to commercialize next-generation therapeutics for diseases representing unmet medical needs and burdens to society, patients, and their families. Reviva’s current pipeline focuses on the central nervous system, respiratory and metabolic diseases. Reviva’s pipeline currently includes two drug candidates, RP5063 (brilaroxazine) and RP1208. Both are new chemical entities discovered in-house. Reviva has been granted composition of matter patents for both RP5063 and R1208 in the United States (U.S.), Europe, and several other countries.

Forward-Looking Statements
This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and the Private Securities Litigation Reform Act, as amended, including those relating to the Company’s product development, clinical and regulatory timelines and expenses, market opportunity, ability to raise sufficient funding, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statements that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions. These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

Corporate Contact:
Reviva Pharmaceuticals Holdings, Inc.
Laxminarayan Bhat, PhD
www.revivapharma.com

Investor Relations Contact:
LifeSci Advisors, LLC
Bruce Mackle
bmackle@lifesciadvisors.com

FAQ

What conferences will Reviva Pharmaceuticals participate in January 2022?

Reviva Pharmaceuticals will participate in the 11th Annual LifeSci Partners Corporate Access Event from January 5-7 and the H.C. Wainwright BioConnect Virtual Conference from January 10-13.

Who is participating in the conferences for Reviva Pharmaceuticals?

Laxminarayan Bhat, Ph.D., the Founder and CEO of Reviva Pharmaceuticals, will be participating in the conferences.

How can investors arrange one-on-one meetings with Reviva Pharmaceuticals?

Investors interested in one-on-one meetings can contact their conference representative or follow the registration links provided in the press release.

What is Reviva Pharmaceuticals' focus in drug development?

Reviva Pharmaceuticals focuses on developing therapies for unmet medical needs in CNS, cardiovascular, metabolic, and inflammatory diseases.

What are the drug candidates in Reviva Pharmaceuticals' pipeline?

Reviva Pharmaceuticals' pipeline includes drug candidates RP5063 (brilaroxazine) and RP1208, which are new chemical entities discovered in-house.